Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?

Tumori Journal Pub Date : 2020-10-01 DOI:10.1177/0300891619882504

D. Facchinelli, A. Parisi, M. Krampera, D. Veneri

{"title":"Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?","authors":"D. Facchinelli, A. Parisi, M. Krampera, D. Veneri","doi":"10.1177/0300891619882504","DOIUrl":null,"url":null,"abstract":"Purpose: We assessed the frequency of triple-positive serology (viral capsid antigen [VCA]–immunoglobulin G [IgG], VCA–immunoglobulin M, Epstein-Barr nuclear antigen–IgG) for Epstein-Barr virus (EBV) in a small number of patients with angioimmunoblastic T-cell lymphoma (AITL) at disease onset. Methods: Nine patients with newly diagnosed AITL were retrospectively enrolled in the present study. For all of them, EBV serology data were available. Results: Of 9 patients, 7 (77.7%) had a triple-positive serology (VCA-IgG, VCA-IgM, EBNA-IgG ) for EBV. These patients were characterized by bone marrow involvement, high incidence of thrombocytopenia, and poor prognosis according to Revised International Prognostic Index and Prognostic Index for Angioimmunoblastic T-cell Lymphoma scores. Conclusion: Assessment of both viremia and serology for EBV could be useful in patients with clinical and laboratory data suggesting lymphoma diagnosis; furthermore, although our data need to be validated in a larger cohort of patients, triple positivity for EBV serology might help to direct the diagnosis toward AITL.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"211 1","pages":"424 - 426"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0300891619882504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We assessed the frequency of triple-positive serology (viral capsid antigen [VCA]–immunoglobulin G [IgG], VCA–immunoglobulin M, Epstein-Barr nuclear antigen–IgG) for Epstein-Barr virus (EBV) in a small number of patients with angioimmunoblastic T-cell lymphoma (AITL) at disease onset. Methods: Nine patients with newly diagnosed AITL were retrospectively enrolled in the present study. For all of them, EBV serology data were available. Results: Of 9 patients, 7 (77.7%) had a triple-positive serology (VCA-IgG, VCA-IgM, EBNA-IgG ) for EBV. These patients were characterized by bone marrow involvement, high incidence of thrombocytopenia, and poor prognosis according to Revised International Prognostic Index and Prognostic Index for Angioimmunoblastic T-cell Lymphoma scores. Conclusion: Assessment of both viremia and serology for EBV could be useful in patients with clinical and laboratory data suggesting lymphoma diagnosis; furthermore, although our data need to be validated in a larger cohort of patients, triple positivity for EBV serology might help to direct the diagnosis toward AITL.

查看原文本刊更多论文

eb病毒(VCA-IgG, VCA-IgM, EBNA-IgG)血清学三阳性是血管免疫母细胞t细胞淋巴瘤的特异性特征吗?

目的:观察少数血管免疫母细胞淋巴瘤(AITL)患者发病时Epstein-Barr病毒(EBV)血清学(病毒衣壳抗原[VCA] -免疫球蛋白G [IgG]、VCA -免疫球蛋白M、Epstein-Barr核抗原- IgG)三阳性的频率。方法:回顾性分析9例新诊断的AITL患者。所有患者均有EBV血清学资料。结果:9例患者中，7例(77.7%)EBV血清三阳性(VCA-IgG、VCA-IgM、EBNA-IgG)。根据修订的国际预后指数和血管免疫母细胞t细胞淋巴瘤预后指数评分，这些患者的特点是骨髓受累，血小板减少发生率高，预后差。结论:EBV的病毒血症和血清学评估可用于临床和实验室资料提示淋巴瘤诊断的患者;此外，尽管我们的数据需要在更大的患者队列中进行验证，但EBV血清学的三重阳性可能有助于指导对AITL的诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori Journal

自引率

0.00%

发文量